Insulin-like Growth Factor Binding Protein-6 and CCI-779, an Ester Analogue of Rapamycin, Additively Inhibit Rhabdomyosarcoma Growth

Abstract

Rhabdomyosarcomas secrete high levels of insulin-like growth factor-II, suggesting this autocrine growth factor plays a major role in the unregulated growth of this childhood cancer. Treatment of Rh30 rhabdomyosarcoma cells with insulin-like growth factor binding protein-6 (IGFBP-6; 1000 ng/ml), which binds insulin-like growth factor-II with high affinity, inhibited growth in vitro (p < 0.001). Co-incubation of cells with rapamycin (1.56 ng/ml), an inhibitor of p70 S6 kinase, and IGFBP-6 (200 ng/ml) resulted in a significant reduction in Rh30 cell number compared to rapamycin or IGFBP-6 alone (p < 0.05 for both). Co-treatment of Rh30 cells with CCI-779 (5 and 50 ng/ml), an ester analogue of rapamycin, and IGFBP-6 (200 or 1000 ng/ml) also inhibited growth in vitro relative to CCI-779 alone (p < 0.01 and p < 0.001, respectively). In a nude mouse model, xenografts of Rh30 cells transfected with a recombinant vector encoding IGFBP-6 (phBP6-E3) showed delayed growth relative to vector control xenografts (27 days vs. 19 days to reach an average tumour volume of 0.5 cm³; p < 0.001). Treatment with CCI-779 (10 mg/kg) of mice inoculated with vector control xenografts, also delayed growth (to 31 days; p = 0.0055) relative to untreated mice with vector control xenografts. Co-treatment with CCI-779 (10 mg/kg) reduced phBP6-E3 transfected xenograft growth even further (to 45 days) compared to vector control xenografts (p < 0.001, day 33). CCI-779 thus acts additively with IGFBP-6 to reduce rhabdomyosarcoma growth both in vitro and in vivo.

Key words

Cancer - Xenograft - Insulin-like Growth Factor

References

• 1 Jones J I, Clemmons D R. Insulin-like growth factors and their binding proteins: biological actions.  Endocr Rev. 1995;  16 3-34
• 2 Bach L A, Rechler M M. Insulin-like growth factors and diabetes.  Diabetes Metab Rev. 1992;  8 229-257
• 3 Bach L A. Insulin-like growth factor binding protein-6: the ”forgotten“ binding protein?.  Horm Metab Res. 1999;  31 226-234
• 4 Daughaday W H. The possible autocrine/paracrine and endocrine roles of insulin-like growth factors of human tumors.  Endocrinology. 1990;  127 1-4
• 5 El-Badry O M, Minniti C P, Kohn E C, Houghton P J, Daughaday W H, Helman L J. Insulin-like growth factor II acts as an autocrine growth and motility factor in human rhabdomyosarcoma tumors.  Cell Growth Differ. 1990;  1 325-331
• 6 Minniti C P, Tsokos M, Newton W A, Helman L J. Specific expression of insulin-like growth factor-II in rhabdomyosarcoma tumor cells.  Am J Clin Pathol. 1994;  101 198-203
• 7 Gallicchio M A, Kneen M, Hall C, Scott A M, Bach L A. Overexpression of insulin-like growth factor binding protein-6 inhibits rhabdomyosarcoma growth in vivo .  Int J Cancer. 2001;  94 645-651
• 8 Shamji A F, Nghiem P, Schreiber S L. Integration of growth factor and nutrient signaling: implications for cancer biology.  Mol Cell. 2003;  12 271-280
• 9 Thimmaiah K N, Easton J, Huang S, Veerka K A, Germain G S, Harwood F C, Houghton P J. Insulin-like growth factor-I-mediated protection from rapamycin-induced apoptosis is independent of Ras-ErkI-Erk2 and phosphatidylinosiyol 3’-kinase-Akt signaling pathways.  Cancer Res. 2003;  63 364-374
• 10 Wan X, Helman L J. Effect of insulin-like growth factor II on protecting myoblast cells against cisplatin-induced apoptosis through the p70 S6 kinase pathway.  Neoplasia. 2002;  4 400-408
• 11 Hosoi H, Dilling M B, Shikata T, Liu L N, Shu L, Ashmun R A, Germain G S. et al . Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells.  Cancer Res. 1999;  59 886-894
• 12 Rosenwald I B, Kaspar R, Rousseau D, Gerhrke L, Leboulch P, Chen J-J, Schmidt E V. et al . Eukaryotic translation initiation factor 4E regulates expression of cyclin D1 at transcriptional and post-transcriptional levels.  J Biol Chem. 1995;  270 21 176-21 180
• 13 Nielsen F C, Ostergaard L, Nielsen J, Christiansen J. Growth-dependent translation of IGF-II mRNA by a rapamycin-sensitive pathway.  Nature. 1995;  377 358-362
• 14 Eng C P, Sehgal S N, Vezina C. Activity of rapamycin (AY-22,989) against transplanted tumors.  J Antibiot (Tokyo). 1984;  37 1231-1237
• 15 Dudkin L, Dilling M B, Cheshire P J, Harwood F C, Hollingshead M, Arbuck S G, Travis R. et al . Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition.  Clin Cancer Res. 2001;  7 1758-1764
• 16 Ciardiello F, Bianco R, Damiano V, de Lorenzo S, Pepe S, de Placido S, Fan Z. et al . Antitumor activity of sequential treatment of topotecan and anti-epidermal growth factor receptor monoclonal antibody C225.  Clin Cancer Res. 1999;  5 909-916
• 17 Geoerger B, Kerr K, Tang C-B, Fung K-M, Powell B, Sutton L N, Phillips P C. et al . Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medullablastoma models as single agent and in combination chemotherapy.  Cancer Res. 2001;  61 1527-1532
• 18 Dilling M B, Dias P, Shapiro D N, German G S, Johnson R K, Houghton P J. Rapamycin selectively inhibits the growth of childhood rhabdomyosarcoma cells through inhibiton of signaling via the type I insulin-like growth factor receptor.  Cancer Res. 1994;  54 903-907
• 19 Neumann G M, Bach L A. The N-terminal disulfide linkages of human insulin-like growth factor-binding protein-6 (hIGFBP-6) and hIGFBP-1 are different as determined by mass spectrometry.  J Biol Chem. 1999;  274 14 587-14 594
• 20 Bach L A, Hsieh S, Brown A L, Rechler M. Recombinant human insulin-like growth factor (IGF) binding protein-6 inhibits IGF-II-induced differentiation of L6A1 myoblasts.  Endocrinology. 1994;  135 2168-2176
• 21 Huseby R A, Maloney T M, McGrath C M. Evidence for a direct growth-stimulating effect of estradiol on human MCF-7 cells in vivo. .  Cancer Res. 1984;  44 2654-2659
• 22 Hosoi H, Dilling M B, Liu L N, Danks M K, Shikata T, Sekulic A, Abraham R T. et al . Studies on the mechanism of resistance to rapamycin in human cancer cells.  Mol Pharamacol. 1998;  54 815-824
• 23 Shi Y, Frankel A, Radvaryi L G, Penn L Z, Miller R G, Mills G B. Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro. .  Cancer Res. 1995;  55 1982-1988
• 24 Muthukkumar S, Ramesh T M, Bondada S. Rapamycin, a potent immunosuppressive drug, causes programmed cell death in B lymphoma cells.  Transplantation. 1995;  60 264-270
• 25 Dilling M B, Germain G S, Dudkin L, Jayaraman A L, Zhang X, Harwood F C, Houghton P J. 4E-binding proteins, the suppressors of eukaryotic initiation factor 4E, are down-regulated in cells with acquired or intrinsic resistance to rapamycin.  J Biol Chem. 2002;  277 13 907-13 917
• 26 Graves L M, Bornfeldt K E, Argast G M, Krebs E G, Kong X, Lin T A, Lawrence J C, Jr. cAMP- and rapamycin-sensitive regulation of the association of eukaryotic initiation factor 4E and the translational regulator PHAS-I in aortic smooth muscle cells.  Proc Natl Acad Sci USA. 1995;  92 7222-7226
• 27 Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, Bruns C J. et al . Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor.  Nat Med. 2002;  8 128-135
• 28 Alexander J W, Raymond E, Depenbrock H, Mekaldi S, Angevin E, Pailler C, Hanauske A. et al .CCI-779, a new rapamycin analog, has antitumour activity at doses inducing only mild cutaneous effects and mucositis: early results of an ongoing phase I study.  In: Proceedings of the 10th AACR-NCI-EORTC International Conference, 1999. Washington, USA; 1999
• 29 Hidalgo M, Rowinsky E K, Erlichman C, Drengler R, Marshall B, Adjei A, Hammond L. et al .Phase I and pharmacological study of CCI-779, a cell cycle inhibitor.  In: Proceedings of the 11th AACR-NCI-EORTC symposium; 2000. Amsterdam, The Netherlands; 2000